Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted chiral allosteric hemoglobin modifiers

a technology of allosteric effectors and modifiers, which is applied in the field of substitution of chiral allosteric effectors, can solve the problems of limited clinical potential of these agents

Inactive Publication Date: 2005-07-14
ALLOS THERAPEUTICS +1
View PDF18 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The new chiral compounds demonstrate increased allosteric activity and stability, effectively reducing hemoglobin's oxygen affinity, potentially improving tissue oxygenation and therapeutic outcomes in conditions like ischemia and tumor treatment.

Problems solved by technology

Lalezari and coworkers demonstrated that shortening the four atom bridge to a three atom urea bridge produced even more potent allosteric modifiers, but their potential as clinical agents was limited due to loss of activity in the presence of serum albumin.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted chiral allosteric hemoglobin modifiers
  • Substituted chiral allosteric hemoglobin modifiers
  • Substituted chiral allosteric hemoglobin modifiers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Scheme 2 Illustrates a Reaction Scheme for Preparing 4-[[(3,5-dimethylanilino)carbonyl]methyl]phenol, a Compound that is Useful as a Precursor in the Preparation of Some of the Table II Compounds

[0024] A mixture of 4-hydroxyphenylacetic acid (20.0 g, 131 mmol) and 3,5-dimethylaniline (15.9 g, 131 mmol) in xylene (100 mL) was stirred for three days at 160° C. with a Dean Stark trap. The mixture was cooled to room temperature and filtered. The solid product obtained was washed with hexane (200 mL), 10% sodium bicarbonate solution (250 mL), water (200 mL), 10% hydrochloric acid (200 mL), and then water (200 mL). The beige solid was air dried to yield 27.7 g, 82.7%. mp 183-185° C.

[0025]1H NMR (CDCl3): δ2.25 (s,6H), 3.60(s,2H), 6.71(s,1H), 6.82(d,2H,J=8.5 Hz), 7.05 (s,2H), 7.13 (d, 2H, J=8.4 Hz).

[0026] Anal: C16H17NO2; Calculated C, 75.27; H, 6.71; N, 5.49; Found C, 75.18, H, 6.69 and N, 5.36

1-[4-[[(3,5-dimethylanilino)carbonyl]phenoxy]-3-methylcyclopentane carboxylic Acid (3)

[0027]...

example 2

[0240] Radiation Oncology. Solid tumors, such as brain metastasis and lung cancers, are oxygen deficient masses. The allostcric effectors of this invention deliver more oxygen to tumors, which increases radical formation that increases tumor killing during radiation.

example 3

[0241] Hypothermia limiting or preventing hypoxia induced irreversive myocardial damage. The allosteric effectors increase the efficiency of oxygen delivery at low blood flow and low temperatures, thus having the ability to prevent myocardial damage.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

Description

[0001] This application is based on U.S. Prov. application No. 60 / 150,351, filed on Aug. 24, 1999 and 60 / 176,635 filed Jan. 19, 2000, incorporated by reference in its entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention generally relates to a family of allosteric effectors of hemoglobin and more specifically to chirality affects of allosteric effectors where the chiral carbon has a substituted carbon ring, a heteroatom ring, or different substituents. The invention includes several new potent enantiomers that are superior than their racemic mixture and other enantiomeric isomer, possessing different degrees of allosteric potency. [0004] 2. Background Description [0005] Human hemoglobin (Hb) is a tetrameric allosteric protein comprised of two alpha and two beta chains and functions to deliver oxygen from the lungs to the many tissues of the body. The four subunits are arranged around a molecular two fold axis creating a central water cavi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/341A61K31/195A61K31/351A61P9/10A61P25/28A61P35/00C07C235/38C07C235/40C07C271/22C07C323/59C07D207/16C07D209/20C07D307/24C07D309/08
CPCC07C235/38C07C235/40C07C323/59C07C2101/08C07D309/08C07D207/16C07D209/20C07D307/24C07C2102/08A61P9/10A61P25/28A61P35/00C07C2601/08C07C2602/08
Inventor ABRAHAM, DONALD J.JOSHI, GAJANAN S.HOFFMAN, STEPHEN J.GRELLA, MELISSADANSO-DANQUAH, RICHMONDYOUSSEF, AMALSAFO, MARTINKULKARNI, SANJEEV
Owner ALLOS THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com